Whither irinotecan?

被引：4

作者：

Blanke, CD ^{[1
]}

机构：

[1] OHSU Canc Inst, Portland, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 22期

关键词：

D O I：

10.1200/JCO.2005.01.914

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：4811 / 4814

页数：4

相关论文

共 20 条

[1] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[2] Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study [J].

Becerra, CR ;

Frenkel, EP ;

Asrfaq, R ;

Gaynor, RB .

INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (06) :868-872

[3]

BLANKE CD, 2002, P AN M AM SOC CLIN, V21, pA127

[4] Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].

Colucci, G ;

Gebbia, V ;

Paoletti, G ;

Giuliani, F ;

Caruso, M ;

Gebbia, N ;

Carteni, G ;

Agostara, B ;

Pezzella, G ;

Manzione, L ;

Borsellino, N ;

Misino, A ;

Romito, S ;

Durini, E ;

Cordio, S ;

Di Seri, M ;

Lopez, M ;

Maiello, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[7] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[8] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[9]

GOLDBERG RM, 2004, PROG P 2004 GI CANC, V1, P148

[10] Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].

Grothey, A ;

Sargent, D ;

Goldberg, RM ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214